Navigation Links
Roche Research Director Grace Ju Hailed as NJABR 'Outstanding Woman of Science'
Date:5/2/2008

NUTLEY, N.J., May 2 /PRNewswire/ -- Roche is pleased to announce that Grace Ju, Ph.D., research director, RNA Therapeutics Discovery Research at Roche, was honored as an "Outstanding Woman of Science" by the New Jersey Association of Biomedical Research (NJABR) at its 2008 Red Carpet Thank You Research Gala held May 1 at the Bridgewater Manor.

Dr. Ju is one of 12 honorees at this year's event, which is also marking the 20th anniversary of NJABR, a nonprofit organization dedicated to promoting the improvement of human and animal health through biomedical research.

"Grace is an outstanding researcher and colleague, an inspiring leader with tremendous dedication to the advancement of science. She is truly deserving of this honor," said Dr. Louis Renzetti, Vice President, Roche Global Head of RNA Therapeutics.

"She is driven by a high degree of integrity and commitment to her science," added Marcia Geremakis, director of Human Resources for Roche Research, Development and Partnering. "She is a true believer in career development and not only has been courageous in broadening her own role in research, but encourages others to do the same."

At Roche, Dr. Ju currently leads research projects aimed at identifying new compounds for the treatment of asthma and other respiratory diseases. Her research efforts focus on the novel technology of siRNA therapeutics.

She joined Roche's Preclinical R&D group in 1981 after training as a postdoctoral fellow at the Roche Institute of Molecular Biology. She has held positions of increasing responsibility within Roche research, and directed preclinical research groups in Molecular Biology, Oncology and Inflammation. A novel compound identified under her research leadership is currently in clinical trials for the treatment of solid tumors.

Dr. Ju has also been an adjunct assistant professor at the University of Medicine and Dentistry of New Jersey (UMDNJ). She is a member of the New York Academy of Sciences, the American Thoracic Society and the New Jersey Cancer Commission.

The recipient of a National Science Foundation Graduate Fellowship, she earned her M.S. and Ph.D. degrees in microbiology and immunology from Albert Einstein College of Medicine in New York. Dr. Ju earned her B.A. summa cum laude in 1974 from the University of California at Berkeley, where she was valedictorian and inducted into Phi Beta Kappa.

"I am pleased that this award also gives much-deserved attention to Roche and its support of women scientists," said Dr. Ju. "Many biomedical scientists choose to go into academia, but I made an active decision to join the pharmaceutical industry. What better use is there for my scientific training, knowledge and background than to participate in discovering and developing drugs that can help people?"

About Roche

Hoffmann-La Roche Inc. (Roche), based in Nutley, N.J., is the U.S. pharmaceuticals headquarters of the Roche Group, one of the world's leading research-oriented healthcare groups with core businesses in pharmaceuticals and diagnostics. For more than 100 years in the U.S., Roche has been committed to developing innovative products and services that address prevention, diagnosis and treatment of diseases, thus enhancing people's health and quality of life. An employer of choice, in 2007 Roche was named Top Company of the Year by Med Ad News, one of the Top 20 Employers (Science) and ranked the No. 1 Company to Sell For (Selling Power). In previous years, Roche has been named as a Top Company for Older Workers (AARP) and one of the Best Companies to Work For in America (Fortune). For additional information about the U.S. pharmaceuticals business, visit our website: http://www.rocheusa.com. Product and treatment information for U.S. healthcare professionals is available at http://www.RocheExchange.com.

All trademarks used or mentioned in this release are protected by law.

Contact(s): Public Affairs

(973) 562-2699


'/>"/>
SOURCE Roche
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Roche Joins Forces With Enon Tabernacle Baptist Church to Provide Free Hepatitis C Testing to the Community
2. Roche Extends Tender Offer for Ventana
3. Pharmasset and Roche to Present R7128 Data at the 14th International Symposium on Hepatitis C Virus and Related Viruses
4. Roche Real-Time HIV Test is Faster and Less Labor-Intensive Than Competitors
5. Indivumed Supports Roche Diagnostics With Immunohistochemistry Services and Clinical Specimens for Biomarker Discovery and Drug Development
6. Amarin Announces Publication of Pre-Clinical Memory Data in Journal of Neurochemistry
7. Med Ad News Honors Roche as Company of the Year
8. MacroChem To Participate in PIPEs Conference October 18th and 19th in New York City
9. MacroChem Announces Michael Zasloff, M.D., Ph.D. Joins Companys Scientific Advisory Board
10. Phase I Results Announced for R1507 From Genmabs Collaboration With Roche
11. Kosan to Reacquire Epothilone Program From Roche
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)...  Anaconda BioMed S.L., a pre-clinical stage medical device ... neuro-thrombectomy system for the treatment of Acute Ischemic Stroke ... to join its Scientific Advisory Board (SAB). The SAB ... scientific and clinical experts to Anaconda BioMed S.L., as ... ® to its clinical phase. The SAB is ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... the World Technology Awards. uBiome is one of just six company finalists in ... , In addition to uBiome, companies nominated as finalists in this year’s awards ...
(Date:12/8/2016)... , Dec. 8, 2016 Soligenix, Inc. ... company focused on developing and commercializing products to treat ... announced today that it will be hosting an Investor ... ET on the origins of innate defense regulators (IDRs) ... review of oral mucositis and the recently announced and ...
(Date:12/8/2016)... , Dec. 8, 2016 Eutilex Co. ... billion KRW (US $18.9M) Series A financing. This financing ... G.N. Tech Venture and SNU Bio Angel. This new ... 30.5 billion KRW (US $27.7M) since its founding in ... to bolster the development and commercialization of its immuno-oncology ...
Breaking Biology Technology:
(Date:12/7/2016)... , Dec. 7, 2016   Veridium , ... the appointment of new CEO James Stickland ... with decades of experience, has served in senior ... where he specialized in expanding a pipeline of ... portfolios. He most recently served as managing director ...
(Date:12/2/2016)... , December 1, 2016 ... (Fingerprint, Voice), Future Technology (Iris Recognition System), Vehicle ... - Global Forecast to 2021", published by MarketsandMarkets, ... Million in 2016, and is projected to grow ... CAGR of 14.06%.      (Logo: http://photos.prnewswire.com/prnh/20160303/792302) ...
(Date:11/29/2016)... 29, 2016   Neurotechnology , a ... recognition technologies, today released FingerCell 3.0, a ... solutions that run on low-power, low-memory microcontrollers. ... less than 128KB of memory, enabling it ... have limited on-board resources, such as: mobile ...
Breaking Biology News(10 mins):